Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name NY-ESO-1-c259T
Trade Name
Synonyms GSK3377794
Drug Descriptions

NY-ESO-1-c259T are autologous, engineered T cells that recognize the cancer testis antigen, CTAG1B (NY-ESO-1), which may result in an immune response against CTAG1B and/or CTAG2 (LAGE-1) expressing cancer cells (PMID: 26193344).



  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Aldesleukin + Cyclophosphamide + Decitabine + NY-ESO-1-c259T Aldesleukin Cyclophosphamide Decitabine NY-ESO-1-c259T 0 1
Cyclophosphamide + Fludarabine + NY-ESO-1-c259T Cyclophosphamide Fludarabine NY-ESO-1-c259T 0 1
NY-ESO-1-c259T NY-ESO-1-c259T 0 4
NY-ESO-1-c259T + Pembrolizumab NY-ESO-1-c259T Pembrolizumab 0 2

Additional content available in CKB BOOST